Dr Louis Nisbet leads BioCity forward

BioCity Nottingham appoints new chairman

Louis Nisbet has become chairman of BioCity Nottingham in the UK. He will oversee the expansion of BioCity’s services to cater for increasing demand from both UK and international tenants. The recent arrival of former AstraZeneca and Pfizer employees launching new ventures, as well as the rapid growth of several existing tenants, makes the BioCity bioscience cluster an attractive central UK business location.

Marlow-based Nisbet is a venture partner with Kurma BioFund, Paris. His early pharmaceutical career in drug discovery research with Roche, Glaxo and Smith Kline gives him a global insight into the issues surrounding the development and commercialisation of new healthcare products and businesses. He will devote time in Nottingham with fellow Board directors to addressing the needs of new life science companies, in particular their financing requirements.

Nisbet said: ‘We will be looking to work with our clients and the large pharmaceutical companies, as well as private investors, to find innovative solutions to facilitate partnerships and financing that will suit everyone.’

You may also like

Finance

BioCity predicts proliferation of workspace amid life science ventures boom

The UK's life science incubator has released the Life Science Start-Up Report with in-depth analysis of emerging businesses
Finance

BioCity makes FT 1000 list of Europe's fastest growing companies

The list identified BioCity and one of the companies on one of its sites in top 200 in the UK for fastest growth
Research & Development

£1.4m to boost growing space for life sciences companies

A £1.4million investment will provide more space for life sciences companies at a Nottingham Enterprise Zone site, thanks to funding from the D2N2 Local Enterprise Partnership, Boots and MediCity
Research & Development

BioCity to support Pfizer scientists facing redundancy

Package of support could lead to new start-up ventures for staff from Sandwich, Kent plant
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Subscribe now